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A beneficial effect of thymosin beta 4 plasmid on suppression
of the extension of myocardial scar formation in rat acute
myocardial infarction
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ABSTRACT  Thymosin beta 4 (Tb4) is a peptide that exists in various kinds of biotissues. 
Recently, a report on its restorative and regenerative actions on the myocardium has attracted 
attention.  Several studies have already reported on the myocardial-restorative effect of Tb4 
peptide in mice.  
　Based on the consideration that local injection of a Tb4 plasmid construct might increase the 
effect of Tb4, in this study, I compared the effect of locally administered Tb4 plasmid with that 
of Tb4 peptide.  
　A rat heterotopic abdominal heart transplantation model (Ono-Lindsey method) was 
employed.  At one week after the transplantation, when the transplanted heart in the model 
rats became stable, both the left anterior descending (LAD) and circumflex (CX) branches of 
the left coronary artery of the transplanted heart were ligated, which led to the development 
of a large myocardial infarct.  The rats were then divided into four groups; Tb4 plasmid (50
μg/50μl) group, the Tb4 peptide (4.0μg/50μl) group, the control PBS injection group, and 
the sham group.  In each group, injection into the myocardium was given at three or four sites 
in the myocardial infarct area.  The myocardial tissues were harvested 4 weeks later, and the 
myocardial-restorative effect of Tb4 was assessed.  The harvested myocardial specimens were 
evaluated using Masson Trichrome stain, and the myocardial scar volume rate was examined. 
　The myocardium scar volume rate was reduced significantly in both the Tb4 plasmid and Tb4 
peptide groups: Tb4 plasmid group (21.7% ± 10.5%; n = 8; p = 0.004 vs. control); Tb4 peptide 
group (22.7% ± 6.9%; n = 7; p = 0.016 vs. control); control group (39.1% ± 13.8%; n = 7; p = 
0.020 vs. sham (n = 6). 
　Significant reduction of the myocardial scar volume rate was observed in both the Tb4 
plasmid and Tb4 peptide groups.  There was no significant difference between the two groups 
in terms of the degree of reduction of the myocardial scar volume.
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BACkground
   Thymosin beta 4 (Tb4) was isolated from the calf 
thymus approximately 40 years ago.  It belongs 
to a family of highly conserved polar 5-kDa 
peptides consisting of 40 to 44 amino acids.  In 
most mammalian tissues, Tb4 is the main peptide, 
representing approximately 70－80% of the total 
beta-thymosin content1).  Tb4 is present in very 
high concentrations in the leucocytes, platelets 
and macrophages2).  Beta-thymosins are often 
referred to as "G-actin sequestering peptides," 
based on their ability to bind monomeric globular 
actin (G-actin) in a 1:1 complex and prevent the 
polymerization of G-actin into actin filaments.  In 
addition to their role as simple actin monomers 
buffering proteins, recent studies have revealed 
that beta-thymosins are actually multifunctional 
peptides involved in cell migration, angiogenesis, 
wound healing, inflammation, morphogenesis, 
and tumor metastasis2,3,12‒16).  While investigating 
the vasculogenic potential of Tb4, Grant and 
his coworkers4) found a fivefold increase of 
Tb4 mRNA expression during morphological 
differentiation of endothelial cells into capillary-
like tubes.  Moreover, Malinda et al 5) and Grant et 
al 6) reported that Tb4 induces an increase in cell-
matrix attachment, proliferation, tube formation, 
peptide internalization, and rearrangement of 
the actin cytoskeleton.  A recent topic of interest 
concerning Tb4 is its involvement in the prevention 
and repair of cardiac damage after myocardial 
infarction by promoting cardiac cell migration and 
survival, demonstrated in mice7).  Other studies have 
identified Tb4-induced adult epicardial cells as a 
viable source of vascular progenitors for continued 
renewal of regressed vessels at a low basal level or 
for sustained neovascularization following cardiac 
injury8).  These findings suggest that Tb4 promotes 
cardiomyocyte migration, survival and repair, and 
reduces the extent of acute myocardial damage. 
Bock-Marquette et al 7) reported that Tb4 formed 
a functional complex with PINCH and integrin-
linked kinase (ILK), resulting in activation of the 
survival kinase Akt (also known as protein kinase B). 
In mice subjected to coronary artery ligation, Tb4 
treatment upregulated the ILK and Akt activities 
in the heart, enhanced early myocyte survival, and 
improved cardiac function. Based on the results of 
these studies, administration of Tb4 for the repair 
of infarcted myocardium may be more effective and 
easier than the strategy involving hematopoietic 
stem cells. Therefore, a rat model of broad acute 
myocardial infarction was employed to evaluate the 
regenerative effect of Tb4; a broad acute myocardial 
infarction was created in a rat heterotopic abdominal 
heart transplantation model (Ono-Lindsey method), 
and the myocardial-restorative effect of the Tb4 
plasmid and peptide was investigated.  
MATErIALS & METHodS
   All experimental procedures were performed in 
accordance with the rules established by the Animal 
Care and Use Committee of Kawasaki Medical 
School (06-021, 07-20).  
Animal preparation
   A total of 56 inbred male Lewis rats (200－250 
g, 9－12w) were purchased from Charles River 
Laboratories, Inc. 
Creating a myocardial infarct in a rat heterotopic 
abdominal heart transplantation model
   The rats were anesthetized with sevoflurane 
(0.5－3%), and a rat heterotopic abdominal heart 
transplantation model (Ono-Lindsey method)9) was 
created.
   The vena cavae of the donor hearts were ligated 
with 3-0 silk sutures.  The ascending aorta and 
main pulmonary artery were transected, leaving 2- 
to 3-mm long vessel origins attached to the heart. 
Heparinized Ringer's sodium solution at 4℃ was 
injected into the coronary arteries bilaterally via 
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the ascending aorta.  The pulmonary vein was 
ligated after the heart beat completely stopped; the 
heart was then harvested.  The donor hearts were 
stored in heparinized Ringer's sodium solution at 
4℃.  Isogenic heterotopic cardiac transplantation 
was performed by end-to-side anastomoses of the 
ascending aorta of the heart graft to the abdominal 
aorta of the recipient.  Then, the graft pulmonary 
artery was anastomosed to the recipient inferior 
vena cava.  The mean cold ischemic time was 46.4 
± 7.45 min.  Declamping of the aorta restored the 
heart beat of the transplanted hearts. 
Injection of Tb4
   One week after the transplantation, when the 
transplant heart state in the model rats became 
stable, ligation of both the LAD and CX branches 
of the left coronary artery of the donor heart 
was performed.  With these procedures, a broad 
myocardial infarction was created.  The rats were 
then divided into four groups; a Tb4 plasmid (50 
μg/50μl) group, a Tb4 peptide (4.0μg/50μl) 
group, a control group, and a sham group.  In each 
group, the injection into the myocardium was made 
into three or four sites of the myocardium of the 
infarction area.  The grafted hearts were harvested 
four weeks later, and the myocardial scar volume 
was evaluated. 
Measurement of the myocardium scar volume rate
   The harvested myocardial specimens were 
evaluated using Masson Trichrome stain, and the 
myocardium scar volume was measured.  "IPLab for 
Windows" (Solution Systems), which is an image 
processing/analysis software, was used.  Statistical 
calculations were performed using a standard t-test 
for variables with 95% confidence intervals.  
rESuLT
   The control group showed inflammatory cell 
infiltration in the myocardial scar tissue on HE 
staining, and the broad myocardial scar formation 
on Masson Trichrome staining (Fig.3).  The scarred 
myocardium was localized just around the coronary 
arteries, and the effectiveness of Tb4 peptide was 
documented (Fig.4).  In the Tb4 plasmid group as 
well as the Tb4 peptide group, the extent of the 
scar formation was limited (Fig.5).  No myocardial 
infarction occurred in the sham group, because 
ligature of the coronary arteries was not performed 
in this group (Fig.6).  The myocardial scar volume 
rate was significantly reduced in the the Tb4 
plasmid and peptide groups: Tb4 plasmid (21.7% 
± 10.5%; n = 8; p = 0.004 vs. control); Tb4 peptide 
group (22.7% ± 6.9%; n = 7; p = 0.016 vs. control); 
control group (39.1% ± 13.8%; n=7; p = 0.020 vs. 
sham (n = 6) (Figs.7, 8).  Significant reduction of 
the myocardium scar volume was observed in the 
Fig. 1.  Structure of plasmid DNA (thymosin beta 4) Fig. 2. Flow chart of the experimental method
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plasmid and peptide groups (Fig.8).  The rate in the 
two groups was comparable, with no significant 
difference.  
dISCuSSIon
   Bock-Marquette et al 7) reported that the ability of 
Tb4 to prevent cell death within 24 h of coronary 
ligation is probably responsible for the decrease of 
the scar volume and improved ventricular function 
observed in mice.  Although the activation of ILK 
by Tb4 is likely to have many cellular effects, 
activation of Akt may be the dominant mechanism 
through which Tb4 promotes cell survival.  Smart 
et al 8) reported that coronary vasculogenesis is 
required to maintain cardiomyocyte survival and 
consequently, appropriate myocardial architecture 
and cardiac function.  The role of Tb4 in coronary 
vessel development may underlie its reported 
ability to play a therapeutic role in cardioprotection 
and repair.  Utilizing the role of Tb4 in vascular 
development in angiogenic therapy for coronary 
artery disease in the adult heart involves releasing 
the adult epicardium from a quiescent state and 
restoring its pluripotency.  Various reports have led 
to Tb4 attracting attention in the field of myocardial 
regenerative medicine.  I considered that use of Tb4 
might be more effective and easier than the strategy 
involving hematopoietic stem cells10).  I used the rat 
heterotopic abdominal heart transplantation model to 
create a large myocardial infarct.  The model could 
be representative of the effect of occlusion of the 
main trunk of the left coronary artery.  I obtained a 
Fig. 3. Myocardium scar in the control group Fig. 4. Myocardium scar in the thymosin beta 4 peptide group
Fig. 5. Myocardium scar in the thymosin beta 4 plasmid group Fig. 6. Myocardium scar in the sham group
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Fig. 8. Myocardium scar volume rate (thymosin beta 4 peptide and plasmid groups vs control group)
Fig. 7. Myocardium scar volume rate (control group vs sham group)
good effect in both the Tb4 peptide and Tb4 plasmid 
groups.  I considered that the grafted myocardial 
tissue might be in a ready state for regeneration, 
because in this rat heterotopic abdominal heart 
transplantation model, the transplanted heart works 
in the condition of non-working beat. 
   Tb4 can be administered safely to both Sprague
―Dawley rats and cynomolgus monkeys at 
doses of up to 50 mg/kg, and has been shown 
to be well-tolerated in both species at all dose 
levels11).  The dose of Tb4 for this study was fixed 
based on the report7) in which 0.4μg of Tb4 was 
injected intramyocardially and 150μg of Tb4 
was administered intraperitoneally into mice.  The 
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beneficial effects of Tb4 were documented by the 
administration of 4.0μg of Tb4 peptide and 50μ
g of Tb4 plasmid in these experiments.  On the 
other hand, some special attention should be paid 
to the possible induction of malignant neoplasms 
following Tb4 administration in the clinical 
setting.  Several studies have reported that beta-
thymosins perform important roles in modulating 
the immune responses, vascular biology, and 
cancer pathogenesis12,13).  In addition, Cha et al 
reported that Tb4 stimulates tumor metastasis by 
activating cell migration and vascularization14).  Tb4 
has also been reported to exert anti-inflammatory 
activity15,16), therefore, it may also promote tumor 
growth by inhibiting immune surveillance14).  Based 
on the results of these studies, it is necessary to 
debate the possibility of induction of malignant 
tumor growth while determining the dose of Tb4 
that must be administered in clinical settings.  The 
effect of administration of the Tb4 plasmid on the 
myocardium has not yet been reported.  In this 
study, the usefulness of Tb4 was evaluated only by 
measuring its effect on the myocardial scar volume 
rate.  However, the mechanisms, by which Tb4 
induces myocardial regeneration, vascularization, 
ischemic defense, and cell survival promotion 
during myocardial repair have not yet been clarified. 
These are important issues that need to be addressed 
in future studies.  
SuMMArY
   A large myocardial infarct was created in a 
rat heterotopic abdominal heart transplantation 
model (Ono-Lindsey method), and the effects 
of myocardial administration of Tb4 plasmid 
and peptide administration in this model were 
invest igated.   Signif icant  reduct ion in the 
myocardium scar volume rate was observed in 
both the plasmid and peptide groups.  The rates in 
the 2 groups were comparable, with no significant 
difference.  The results of this study indicate that the 
use of Tb4 might be more effective and easier than 
the strategy involving hematopoietic stem cells. 
Use of Tb4 has begun to attract attention in the field 
of myocardial regenerative medicine.  
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